407 related articles for article (PubMed ID: 35589670)
1. Recent advances in IAP-based PROTACs (SNIPERs) as potential therapeutic agents.
Wang C; Zhang Y; Shi L; Yang S; Chang J; Zhong Y; Li Q; Xing D
J Enzyme Inhib Med Chem; 2022 Dec; 37(1):1437-1453. PubMed ID: 35589670
[TBL] [Abstract][Full Text] [Related]
2. Specific non-genetic IAP-based protein erasers (SNIPERs) as a potential therapeutic strategy.
Ma Z; Ji Y; Yu Y; Liang D
Eur J Med Chem; 2021 Apr; 216():113247. PubMed ID: 33652355
[TBL] [Abstract][Full Text] [Related]
3. Targeted protein degradation and drug discovery.
Naito M
J Biochem; 2022 Jul; 172(2):61-69. PubMed ID: 35468190
[TBL] [Abstract][Full Text] [Related]
4.
Ohoka N; Okuhira K; Ito M; Nagai K; Shibata N; Hattori T; Ujikawa O; Shimokawa K; Sano O; Koyama R; Fujita H; Teratani M; Matsumoto H; Imaeda Y; Nara H; Cho N; Naito M
J Biol Chem; 2017 Mar; 292(11):4556-4570. PubMed ID: 28154167
[TBL] [Abstract][Full Text] [Related]
5. [Development of Protein Knockdown Technology as Emerging Drug Discovery Strategy].
Ohoka N
Yakugaku Zasshi; 2018; 138(9):1135-1143. PubMed ID: 30175757
[TBL] [Abstract][Full Text] [Related]
6. Selective Degradation of Target Proteins by Chimeric Small-Molecular Drugs, PROTACs and SNIPERs.
Ishikawa M; Tomoshige S; Demizu Y; Naito M
Pharmaceuticals (Basel); 2020 Apr; 13(4):. PubMed ID: 32326273
[TBL] [Abstract][Full Text] [Related]
7. Proteolysis-targeting chimaeras (PROTACs) as pharmacological tools and therapeutic agents: advances and future challenges.
Wang C; Zhang Y; Zhang T; Shi L; Geng Z; Xing D
J Enzyme Inhib Med Chem; 2022 Dec; 37(1):1667-1693. PubMed ID: 35702041
[TBL] [Abstract][Full Text] [Related]
8. Synthesis of SNIPERs against BCR-ABL with kinase inhibitors and a method to evaluate their growth inhibitory activity derived from BCR-ABL degradation.
Cho N; Naito M
Methods Enzymol; 2023; 681():41-60. PubMed ID: 36764763
[TBL] [Abstract][Full Text] [Related]
9. Protein Knockdown Technology: Application of Ubiquitin Ligase to Cancer Therapy.
Ohoka N; Shibata N; Hattori T; Naito M
Curr Cancer Drug Targets; 2016; 16(2):136-46. PubMed ID: 26560118
[TBL] [Abstract][Full Text] [Related]
10. Strategies to Reduce the On-Target Platelet Toxicity of Bcl-x
Negi A; Voisin-Chiret AS
Chembiochem; 2022 Jun; 23(12):e202100689. PubMed ID: 35263486
[TBL] [Abstract][Full Text] [Related]
11. SNIPERs-Hijacking IAP activity to induce protein degradation.
Naito M; Ohoka N; Shibata N
Drug Discov Today Technol; 2019 Apr; 31():35-42. PubMed ID: 31200857
[TBL] [Abstract][Full Text] [Related]
12. PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics.
Khan S; He Y; Zhang X; Yuan Y; Pu S; Kong Q; Zheng G; Zhou D
Oncogene; 2020 Jun; 39(26):4909-4924. PubMed ID: 32475992
[TBL] [Abstract][Full Text] [Related]
13. Expansion of targeted degradation by Gilteritinib-Warheaded PROTACs to ALK fusion proteins.
Yokoo H; Tsuji G; Inoue T; Naito M; Demizu Y; Ohoka N
Bioorg Chem; 2024 Apr; 145():107204. PubMed ID: 38377822
[TBL] [Abstract][Full Text] [Related]
14. Small-molecule PROTACs: novel agents for cancer therapy.
Wan Y; Yan C; Gao H; Liu T
Future Med Chem; 2020 May; 12(10):915-938. PubMed ID: 32270707
[TBL] [Abstract][Full Text] [Related]
15. PROTACs technology for targeting non-oncoproteins: Advances and perspectives.
Wang C; Zhang Y; Xing D; Zhang R
Bioorg Chem; 2021 Sep; 114():105109. PubMed ID: 34175722
[TBL] [Abstract][Full Text] [Related]
16. Different Degradation Mechanisms of Inhibitor of Apoptosis Proteins (IAPs) by the Specific and Nongenetic IAP-Dependent Protein Eraser (SNIPER).
Ohoka N; Ujikawa O; Shimokawa K; Sameshima T; Shibata N; Hattori T; Nara H; Cho N; Naito M
Chem Pharm Bull (Tokyo); 2019 Mar; 67(3):203-209. PubMed ID: 30369550
[TBL] [Abstract][Full Text] [Related]
17. Targeted Protein Degradation by Chimeric Small Molecules, PROTACs and SNIPERs.
Naito M; Ohoka N; Shibata N; Tsukumo Y
Front Chem; 2019; 7():849. PubMed ID: 31921772
[TBL] [Abstract][Full Text] [Related]
18. Developments of PROTACs technology in immune-related diseases.
Wang C; Zhang Y; Deng J; Liang B; Xing D
Eur J Med Chem; 2023 Mar; 249():115127. PubMed ID: 36724631
[TBL] [Abstract][Full Text] [Related]
19. Homo-PROTACs: bivalent small-molecule dimerizers of the VHL E3 ubiquitin ligase to induce self-degradation.
Maniaci C; Hughes SJ; Testa A; Chen W; Lamont DJ; Rocha S; Alessi DR; Romeo R; Ciulli A
Nat Commun; 2017 Oct; 8(1):830. PubMed ID: 29018234
[TBL] [Abstract][Full Text] [Related]
20. Development of Chimeric Molecules That Degrade the Estrogen Receptor Using Decoy Oligonucleotide Ligands.
Naganuma M; Ohoka N; Tsuji G; Tsujimura H; Matsuno K; Inoue T; Naito M; Demizu Y
ACS Med Chem Lett; 2022 Jan; 13(1):134-139. PubMed ID: 35059133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]